Prostate Cell News Volume 1.00 | Jan 8 2010

TOP STORY

Experimental Drug Shows Promise Against Brain and Prostate Cancers
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies. [UT Southwestern Medical Center, Dallas]

		Use ALDEFLUOR® to Detect Prostate Precursor Cells by STEMCELL Technologies
		WATCH THE VIDEO

Sexual Function Does Not Continuously Decline after Radiation Therapy Treatments for Prostate Cancer
Sexual function in prostate cancer patients receiving external beam radiation therapy decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought. [Jefferson Medical College of Thomas Jefferson University, Philadelphia; Thomas Jefferson University Hospital, Philadelphia; University of California, Davis, Sacramento]

Report Suggests Similar Levels of Effectiveness Among Management and Treatment Options for Low-Risk Prostate Cancer
A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably. [Institute for Clinical and Economic Review, Boston]

Rethinking Screening for Breast Cancer And Prostate Cancer
The analysis of the impact of current screening for breast and prostate cancer found significant room for improvement. Screening has led to an increase in cancers detected, many of which are not life threatening, however, success in preventing more advanced stage cancers has been limited.  Importantly, medical professionals propose a strategy for moving forward. [University of California, San Francisco; University of Texas Health Science Center, San Antonio]

		Optimized Enzymes and Protocols for Prostate Tissue Dissociation by STEMCELL Technologies
		CLICK HERE TO LEARN MORE

CURRENT PUBLICATIONS

LABORATORY RESEARCH

Altered Expression of Neurotensin Receptors is Associated with the Differentiation State of Prostate Cancer
Recent evidence suggests that neurotensin receptors (NTR) are recruited in advanced prostate cancer as an alternative growth pathway in the absence of androgens. In this study, researchers assessed the potential use of NTR as targets by analyzing NTR expression patterns in human prostate cell lines and primary prostate tumor cell cultures derived from patient samples. [Cancer Res]

ErbB3 Binding Protein 1 (EBP1) Represses Metastasis-Promoting Gene Anterior Gradient Protein 2 (AGR2) in Prostate Cancer
Overexpression of AGR2 was found to promote the motility and invasiveness of nonmetastatic LNCaP tumor cells, whereas silencing of AGR2 in the metastatic derivative C4-2B blocks invasive behavior.  The anti-invasive effect of EBP1, a putative repressor of AGR2, was shown to occur, at least in part, through its ability to inhibit AGR2 expression. [Cancer Res]

Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
To determine the relationship between chromosome 8 changes, and prostate cancer phenotype and prognosis, a set of 1.954 fully annotated prostate cancers were analyzed in a tissue microarray format by fluorescence in situ hybridization. [Clin Cancer Res]

E-Cadherin-Mediated Survival of Androgen Receptor-Expressing Secretory Prostate Epithelial Cells Derived from a Stratified in vitro Differentiation Model
This study describes the development of a differentiation system that is amenable to functional and biochemical analysis and its application to deciphering the survival pathways in differentiated androgen receptor-expressing epithelial cells. [J Cell Sci]

FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells
The upregulation of Hsp90 co-chaperone FKBP51 in LAPC-4 androgen-independent tumors grown in castrated mice was illustrated and the molecular mechanism for how FKBP51 regulates androgen receptor activity was described. [Mol Cell Biol]

CLINICAL RESEARCH

Cardiovascular Mortality after Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
Researchers assessed the relationship between gonadotropin-releasing hormone agonists and cardiovascular mortality in a large randomized phase III trial of men treated with or without adjuvant goserelin after radiation therapy for locally advanced prostate cancer. [J Clin Oncol]

Mortality in Men with Localized Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormone Therapy
Discrepancies exist regarding the impact of neoadjuvant hormone therapy (NHT) on the risk of all-cause mortality (ACM) in men who receive brachytherapy for localized prostate cancer. Therefore, the objective of the current study was to examine the effect of NHT on the risk of ACM in men with prostate cancer who receive brachytherapy. [Cancer]

A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients with High-Risk Prostate Cancer
The purpose of this study was to compare the toxicity and efficacy of hypofractionated (62 Gy/20 fractions/5 weeks, 4 fractions per week) vs. conventional fractionation radiotherapy (80 Gy/40 fractions/8 weeks) in patients with high-risk prostate cancer. [Int J Radiat Oncol Biol Phys]

Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate-Specific Antigen
Studies have suggested that statin (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors) medication use may decrease prostate-specific antigen (PSA) in healthy men. Here, researchers determined the effect of preoperative statin use on total preoperative PSA and the risk of biochemical recurrence in patients with prostate cancer presenting for radical prostatectomy. [J Urol]

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
Since EGFR and HER2 overexpression has been seen in prostate cancer and appears to correlate with a worse clinical outcome, Lapatinib may represent a novel therapeutic strategy in prostate cancer. This phase II multicenter clinical trial is the first to evaluate Lapatinib in early stage, hormonally untreated recurrent or metastatic prostate cancer. [Am J Clin Oncol]

		Detect 7x More Prostate Epithelial Progenitor Cells with ProstaCult™ by STEMCELL Technologies
		CLICK HERE TO LEARN HOW

The Prostate Cancer Foundation to Fund More Than 30 New Projects to Accelerate Prostate Cancer Research
The Prostate Cancer Foundation announced that it will fund at least 10 new Creativity and 20 new multi-year Young Investigator Awards in the first half of 2010. These grants will support innovative research ideas and encourage new ideas from some of the brightest young minds in the field of cancer research.

OncoGenex Announces that a Randomized, Investigator-Sponsored Phase II Study Evaluating OGX-427 has Received Grant Funding
OncoGenex Pharmaceuticals, Inc. recently announced that a randomized, controlled, investigator-sponsored phase II clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer has received grant funding.

United Kingdom National Stem Cell Network (UKNSCN) Funding and New Management Structure Announced
The UKNSCN is delighted to announce that its Research Council sponsors – BBSRC, MRC, EPSRC and ESRC – have increased their core funding of the Network to £180k per annum for the next two financial years.

Massachusetts Medical Society (MMS) Urges Passage of Smoking, Cancer Bills
MMS recently testified before the state Legislature’s Joint Committee on Financial Services in support of four health-related bills. Two of the bills would increase coverage and programs for smoking cessation, one would provide for prostate-cancer screening, and one would ensure appropriate in-patient coverage for breast-cancer patients. [Massachusetts Medical Society, United States]

Cancellation of Notice NOT-CA-09-017, Clarification of Page Limitations for Research Plan in PAR-09-026 Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) (NOT-OD-10-029) [National Institutes of Health, United States]

Notice on P40 Page Limits (NOT-RR-10-002) [National Institutes of Health, United States]

Academic Research Enhancement Award (Parent R15) (PA-10-070) [National Institutes of Health, United States]

Technologies and Software to Support Integrative Cancer Biology Research (R43/R44) [Small Business Innovation Research, United States]

7th Meeting of the EAU Section of Oncological Urology
January 15-17, 2010
Vienna, Austria

Stem Cells and Regenerative Medicine World Congress
January 20-21, 2010
San Francisco, United States

Phacilitate Cell and Gene Therapy Forum 2010
January 25-27, 2010
Washington DC, United States

CHI’s Molecular Medicine Tri-Conference 2010
February 3-5, 2010
San Francisco, United States

AACR/JCA Joint Conference: Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics
February 5-9, 2010
Waikoloa, United States

SMi’s Second Annual Stem Cells 2010
February 15-16, 2010
London, United Kingdom

Keystone Symposia: Stem Cell Differentiation and Dedifferentiation (B4)
February 15-20, 2010
Keystone, United States

5th Annual Stem Cell Summit
February 16, 2010
New York, United States

Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer
February 24-27, 2010
Washington, DC, United States

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research Annual Meeting
April 17-21, 2010
Washington, DC, United States

JOB OPPORTUNITIES

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!